tolterodine tartrate

CLINICAL USE

Treatment of urinary frequency, urgency and incontinence

DOSE IN NORMAL RENAL FUNCTION

1–2 mg twice daily M/R: 4 mg daily

PHARMACOKINETICS

Molecular weight : 475.6

%Protein binding : 96

%Excreted unchanged in urine : <1

Volume of distribution (L/kg) : 0.9–1.6

half-life – normal/ESRD (hrs) : 2–3 (10 hours in poor metabolisers)/– MR: 6/–

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

30–50 Dose as in normal renal function. Use with caution 10–30 1 mg twice daily. Use with caution

<10 : 1 mg twice daily. Use with caution

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD : Unlikely to be dialysed. Dose as in GFR <10 mL/min

HD : Unlikely to be dialysed. Dose as in GFR <10 mL/min

HDF/high flux : Unlikely to be dialysed. Dose as in GFR <10 mL/min

CAV/VVHD : Unlikely to be dialysed. Dose as in GFR=10–30 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

None known

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Active metabolites may accumulate in renal failure Modified release preparation is not suitable for renal patients Use with caution in patients at risk of QT

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home